Skip to main content

Advertisement

Fig. 7 | Molecular Neurodegeneration

Fig. 7

From: Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Fig. 7

Armanezumab inhibited cytotoxicity of oligomeric recombinant tau protein. a SH-SY5Y human neuroblastoma cell line and mouse primary neurons b were incubated with tau oligomers in the presence or absence of Armanezumab or control IgG. Control cells were treated with vehicle, and cell viability was assayed in all cultures using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Data were collected (four replicates) and expressed as percentages of control ± SD

Back to article page